SEARCH SITE

VIRGINIA LAW PORTAL

SEARCHABLE DATABASES

ACROSS SESSIONS

Developed and maintained by the Division of Legislative Automated Systems.

2002 SESSION

  • | print version

SB 218 Newborn testing.

Introduced by: Patricia S. Ticer | all patrons    ...    notes | add to my profiles | history

SUMMARY AS PASSED:

Newborn testing. Adds to the list of inherited disorders for which newborn testing is required by the Commonwealth, a fatty acid oxidation disorder known as MCAD or MCADH, i.e., medium-chain acyl-CoA dehydrogenase, which inhibits the proper metabolizing of stored fat. Individuals with MCAD, if left untreated, have episodes of hypoglycemia and Reye’s syndrome, which may result in fever, vomiting, coma, disorientation, and fatty infiltration of the liver. Implementation of this test will require the purchase of tandem mass spectrometers, which are technologically advanced analytic instruments that can be used to test newborns for more than 20 treatable metabolic disorders by sorting molecules in blood samples according to weight in a similar fashion to machines that sort coins. This provision will only become effective one year after the date that sufficient funds are appropriated or otherwise secured to (i) support the Virginia Department of Health's costs for start-up professional and family education and (ii) the purchase of the necessary equipment for implementation of the testing program in the Division of Consolidated Laboratories.

SUMMARY AS PASSED SENATE:

Newborn testing. Adds to the list of inherited disorders for which newborn testing is required by the Commonwealth, a fatty acid oxidation disorder known as MCAD or MCADH, i.e., medium-chain acyl-CoA dehydrogenase, which inhibits the proper metabolizing of stored fat. Individuals with MCAD, if left untreated, have episodes of hypoglycemia and Reye’s syndrome, which may result in fever, vomiting, coma, disorientation, and fatty infiltration of the liver. Implementation of this test will require the purchase of tandem mass spectrometers, which are technologically advanced analytic instruments that can be used to test newborns for more than 20 treatable metabolic disorders by sorting molecules in blood samples according to weight in a similar fashion to machines that sort coins. This provision will only become effective one year after the date that sufficient funds are appropriated or otherwise secured to (i) support the Virginia Department of Health's costs for start-up professional and family education and (ii) the purchase of the necessary equipment for implementation of the testing program in the Division of Consolidated Laboratories.

SUMMARY AS INTRODUCED:

Newborn testing. Adds to the list of inherited disorders for which newborn testing is required by the Commonwealth, a fatty acid oxidation disorder known as MCAD or MCADH, i.e., median-chain acyl-CoA dehydrogenase, which inhibits the proper metabolizing of stored fat. Individuals with MCAD, if left untreated, have episodes of hypoglycemia and Reye’s syndrome, which may result in fever, vomiting, coma, disorientation, and fatty infiltration of the liver. Implementation of this test will require the purchase of tandem mass spectrometers, which are technologically advanced analytic instruments that can be used to test newborns for more than 20 treatable metabolic disorders by sorting molecules in blood samples according to weight in a similar fashion to machines that sort coins. This act will become effective on January 1, 2004. A third enactment clause requires, prior to the effective date of this act, that the Commissioner and Department of Health and the Director of the Division of Consolidated Laboratory Services must seek assistance from a private, nonprofit organization in the purchase of at least one tandem mass spectrometer.